Ovarian cancer is uncommon but not rare by medical standards. In the United States, a disease is officially classified as “rare” when it affects fewer than 200,000 people. Ovarian cancer exceeds that threshold, with an estimated 21,010 new cases expected in 2026 alone. Still, it represents a small fraction of all cancer diagnoses, and most women will never develop it.
That relatively low frequency creates a paradox: ovarian cancer isn’t common enough for routine screening to work well, yet it’s deadly enough to rank as the fourteenth leading cause of cancer death in the country. About 12,450 people are expected to die from it in 2026. Understanding where ovarian cancer falls on the spectrum between “common” and “rare” matters because it shapes everything from screening recommendations to how quickly symptoms get investigated.
How Common Ovarian Cancer Actually Is
To put the numbers in perspective, breast cancer produces roughly 300,000 new cases per year in the U.S., and lung cancer about 230,000. Ovarian cancer’s 21,000 annual cases make it far less prevalent than either. A woman’s lifetime risk of developing ovarian cancer sits around 1 in 78, compared to roughly 1 in 8 for breast cancer.
That said, ovarian cancer punches above its weight in terms of mortality. Many more common cancers have higher survival rates because they’re caught earlier or respond better to treatment. Ovarian cancer’s combination of vague symptoms and limited screening options means it’s frequently diagnosed at an advanced stage, which drives the high death toll relative to its case count.
Why There’s No Routine Screening
One reason ovarian cancer remains so dangerous despite being relatively uncommon is that no reliable screening test exists for the general population. The U.S. Preventive Services Task Force recommends against routine screening for women who aren’t at high risk, and the reason comes down to math.
Because ovarian cancer is uncommon, screening tests produce a high rate of false positives. In large clinical trials, blood tests and transvaginal ultrasounds flagged many women who turned out not to have cancer. In one major UK trial, 44.2% of women without ovarian cancer received at least one positive result over the course of multiple screening rounds. Those false alarms aren’t harmless: up to 3.25% of screened women in some trial groups underwent surgery to investigate a positive result they didn’t need, and up to 15% of those women experienced major surgical complications.
The core problem is that when a disease is uncommon, even a fairly accurate test will flag far more healthy people than sick ones. Screening works best for cancers that are either very common (like breast cancer) or have highly precise tests. Ovarian cancer currently has neither advantage.
Symptoms That Often Get Overlooked
Without a screening tool, catching ovarian cancer early depends on recognizing symptoms. The challenge is that the most common symptoms are things many women experience routinely for other reasons: bloating, pelvic or abdominal pain, trouble eating or feeling full quickly, and urinary urgency or frequency.
The distinguishing factor is persistence and change. When these symptoms are caused by ovarian cancer, they tend to be new, more frequent, or more severe than what’s normal for you. The American Cancer Society suggests that experiencing these symptoms more than 12 times a month warrants a medical evaluation. Other symptoms that can accompany ovarian cancer include fatigue, back pain, pain during sex, constipation, irregular bleeding, and abdominal swelling paired with weight loss. None of these symptoms on their own indicate cancer, but a cluster of them appearing together and persisting is worth investigating.
Some Types Are Rarer Than Others
Ovarian cancer isn’t a single disease. About 90% of cases are epithelial tumors, which start in the cells covering the outer surface of the ovary. These are the most common type and the kind most people mean when they refer to ovarian cancer.
The remaining 10% includes germ cell tumors, sex cord stromal tumors, and other uncommon varieties. These genuinely are rare cancers. In younger women (under 40), the breakdown shifts noticeably: germ cell tumors account for about 22.5% of cases in that age group, compared to 72% epithelial. Sex cord stromal tumors make up about 3.2%. These rarer subtypes often behave differently, tend to respond better to treatment, and are more likely to be caught at an earlier stage.
Who Faces Higher Risk
For most women, the lifetime risk of ovarian cancer is low. But certain factors push that risk dramatically higher. The most significant is carrying a BRCA1 or BRCA2 gene mutation. Women with a BRCA1 mutation face a 45% to 60% lifetime risk of ovarian cancer. For BRCA2 mutation carriers, the risk ranges from 11% to 35%. Compare that to the roughly 1.3% lifetime risk in the general population, and the difference is striking.
Other factors that increase risk include a family history of ovarian or breast cancer (even without a known gene mutation), increasing age, never having been pregnant, and certain hormone therapy use. Factors that lower risk include having used oral contraceptives, having had pregnancies, and breastfeeding, all of which reduce the number of times a woman ovulates over her lifetime.
For women with known BRCA mutations or strong family histories, the conversation about ovarian cancer looks very different than it does for the general population. Genetic counseling and preventive strategies, including the option of surgically removing the ovaries and fallopian tubes after childbearing is complete, can substantially reduce risk in this group.
The Bottom Line on Rarity
Ovarian cancer occupies an uncomfortable middle ground. It’s uncommon enough that most women will never get it and that population-wide screening does more harm than good. But it’s not so rare that you can ignore it. Its low frequency is precisely what makes it dangerous: it doesn’t get caught by routine tests, its symptoms mimic everyday complaints, and by the time it’s diagnosed, it has often spread. Knowing your family history, paying attention to persistent symptom changes, and understanding your personal risk level are the most practical tools available right now.